Loading…
Eli Lilly and Company is projected to rise to $1,420.66 by 2027, a +20% move from its current price of $1,188.58. LLY is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $1,167.77 | $1,189.14 | $1,210.90 | +0.05% |
| Jul 14 | $1,159.58 | $1,189.70 | $1,220.60 | +0.09% |
| Jul 15 | $1,153.47 | $1,190.27 | $1,228.24 | +0.14% |
| Jul 16 | $1,148.42 | $1,190.83 | $1,234.80 | +0.19% |
| Jul 17 | $1,144.05 | $1,191.39 | $1,240.69 | +0.24% |
| Jul 18 | $1,140.17 | $1,191.95 | $1,246.09 | +0.28% |
| Jul 19 | $1,136.66 | $1,192.52 | $1,251.12 | +0.33% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1,136.66 | $1,192.52 | $1,251.12 | +0.33% |
| Week 2 | $1,117.98 | $1,196.47 | $1,280.46 | +0.66% |
| Week 3 | $1,104.71 | $1,200.43 | $1,304.43 | +1.00% |
| Week 4 | $1,094.22 | $1,204.40 | $1,325.69 | +1.33% |
| Week 5 | $1,085.48 | $1,208.39 | $1,345.22 | +1.67% |
| Week 6 | $1,077.98 | $1,212.39 | $1,363.57 | +2.00% |
| Week 7 | $1,071.41 | $1,216.41 | $1,381.03 | +2.34% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis.
The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A.
for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; and BioArctic AB (publ) for new treatment. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Eli Lilly and Company (LLY) is priced at $1,229.93 per share, with a market cap of $1.1T and a market rank of 12.
The 30-day price range runs from $1,081.43 to $1,398.82, with support at $988.09 and resistance at $1,229.93.
The RSI (14) is 70 and the sentiment is BULLISH. The stock trades with a view of its moving averages, with SMA50 at $1,037.82 and SMA200 at $978.29.
The year-by-year forecast suggests a bullish trajectory, starting with a 2026 average price of $1,229.93 and rising toward 2050, where the average is $11,671.14. The forecast implies ROI figures from 0 in 2026 to 848.9 by 2050, signaling substantial long-term upside.
A major floor 28.4% below — a decisive break under it would weaken the trend.
The nearest floor, 10.5% below — buyers have tended to step in here.
The nearest ceiling, 4.0% above — a clean break opens room to run.
A major ceiling 12.2% above — clearing it would confirm fresh momentum.
Key LLY support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of LLY market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1,211.40 | Sell | $1,205.21 | Sell |
| MA 10 | $1,210.01 | Sell | $1,196.49 | Sell |
| MA 20 | $1,165.53 | Buy | $1,170.53 | Buy |
| MA 50 | $1,086.75 | Buy | $1,106.23 | Buy |
| MA 100 | $1,020.51 | Buy | $1,053.80 | Buy |
| MA 200 | $996.33 | Buy | $995.31 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 57.13 | Neutral |
| Stoch RSI (14) | 12.12 | Buy |
| CCI (20) | 34.55 | Neutral |
| Williams %R (14) | -35.20 | Info |
| MACD (12,26,9) | -0.88 | Sell |
| ROC (12) | 7.36 | Buy |
| Bollinger %B (20,2) | 0.62 | Neutral |
| Stochastic %K (14) | 64.80 | Neutral |
| TRIX (15) | 0.49 | Buy |
| Awesome (5,34) | 72.90 | Buy |
| Ultimate (7,14,28) | 53.17 | Neutral |
| Momentum (10) | 60.89 | Buy |
| Aroon Osc (25) | 88.00 | Buy |
| Hull MA (9) | 1214.64 | Sell |
| ADX (14) | 27.18 | Buy |
| ATR (14) | 19.38 | Info |
The 30-day technical picture is bullish, with RSI(14) at 70 and a positive near-term bias.
Key moving averages are SMA50 at $1,037.82 and SMA200 at $978.29, with a defined support at $988.09 and resistance at $1,229.93. The 30-day price range spans from $1,081.43 to $1,398.82, outlining the recent volatility band for the stock.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $851.21 | $1,188.58 | $1,587.82 | 0% | Neutral | |
| $1,163.55 | $1,420.66 | $1,813.51 | +20% | Neutral | |
| $1,254.57 | $1,560.58 | $2,046.02 | +31% | Bullish | |
| $1,397.98 | $1,765.81 | $2,364.39 | +49% | Bullish | |
| $1,590.35 | $2,035.92 | $2,775.18 | +71% | Bullish | |
| $1,886.52 | $2,444.57 | $3,384.88 | +106% | Bullish | |
| $2,081.08 | $2,727.16 | $3,829.89 | +129% | Bullish | |
| $2,293.71 | $3,037.45 | $4,320.88 | +156% | Bullish | |
| $2,468.23 | $3,301.08 | $4,752.03 | +178% | Bullish | |
| $2,476.68 | $3,343.74 | $4,867.02 | +181% | Bullish | |
| $3,884.11 | $5,469.38 | $8,342.77 | +360% | Bullish | |
| $6,851.65 | $10,347.52 | $16,918.98 | +771% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $851.21 | $1,188.58 | $1,405.16 | +0.00% |
| August 2026 | $1,021.96 | $1,196.20 | $1,430.41 | +0.64% |
| September 2026 | $1,055.07 | $1,240.90 | $1,495.47 | +3.74% |
| October 2026 | $1,082.34 | $1,278.21 | $1,550.62 | +3.01% |
| November 2026 | $1,079.79 | $1,279.63 | $1,560.92 | +0.11% |
| December 2026 | $1,089.30 | $1,295.08 | $1,587.82 | +1.21% |
Click any year to see its month-by-month LLY forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The LLY price prediction for 2026 points to an average of $1,188.58 (low $851.21, high $1,587.82) — a potential gain of 0% on today's $1,188.58. Price action looks broadly range-bound.
In 2027, LLY is projected to trade between $1,163.55 and $1,813.51, averaging $1,420.66 — a potential gain of +20% from today's $1,188.58. That is up +20% on the projected 2026 average. A consolidation phase looks the most probable path here.
Eli Lilly and Company's 2028 outlook centres on $1,560.58, within a $1,254.57 to $2,046.02 range. That is up +10% on the projected 2027 average. That marks a +31% change versus current levels. Momentum favours further upside here.
By 2029, LLY could reach as high as $2,364.39, with a base case around $1,765.81 and support toward $1,397.98 — roughly +49% from $1,188.58. Buyers look set to stay in control over this stretch.
Expect LLY to range from $1,590.35 to $2,775.18 through 2030. The $2,035.92 average target implies a +71% move from current prices. That is up +15% on the projected 2029 average. Momentum favours further upside here.
The LLY price prediction for 2031 points to an average of $2,444.57 (low $1,886.52, high $3,384.88) — a potential gain of +106% on today's $1,188.58. Buyers look set to stay in control over this stretch.
In 2032, LLY is projected to trade between $2,081.08 and $3,829.89, averaging $2,727.16 — a potential gain of +129% from today's $1,188.58. That is up +12% on the projected 2031 average. Momentum favours further upside here.
Eli Lilly and Company's 2033 outlook centres on $3,037.45, within a $2,293.71 to $4,320.88 range. That is up +11% on the projected 2032 average. That marks a +156% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, LLY could reach as high as $4,752.03, with a base case around $3,301.08 and support toward $2,468.23 — roughly +178% from $1,188.58. Momentum favours further upside here.
Expect LLY to range from $2,476.68 to $4,867.02 through 2035. The $3,343.74 average target implies a +181% move from current prices. That is up +1% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The LLY price prediction for 2040 points to an average of $5,469.38 (low $3,884.11, high $8,342.77) — a potential gain of +360% on today's $1,188.58. Momentum favours further upside here.
In 2050, LLY is projected to trade between $6,851.65 and $16,918.98, averaging $10,347.52 — a potential gain of +771% from today's $1,188.58. That is up +89% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in LLY today (≈ 0.84134 LLY) could be worth
$8,705.78
+$7,705.78 (+771%) by 2050 · US Dollar
Based on the average projected LLY price of $10,347.52 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in LLYwould be worth at today's price.
$1,000 invested in LLY on Jul 10, 2025 (≈ 1.264782 LLY) would be worth
$1,503.29
+$503.29 (+50.3%) today · 1.50× · US Dollar
Based on a LLY entry price of $790.65 vs. today's $1,188.58.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1,213.91 | $979.13 | -2.1% |
| 1 month ago | $1,136.37 | $1,045.94 | +4.6% |
| 3 months ago | $939.47 | $1,265.16 | +26.5% |
| 6 months ago | $1,081 | $1,099.52 | +10.0% |
| 1 year ago | $790.65 | $1,503.29 | +50.3% |
| All time (5.0y) ago | $235.3 | $5,051.34 | +405.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our LLY forecast.
Our base-case forecast reaches $2,400.00 around 2031.
Implied market cap at $2,400.00: $2.14T
The multi-year forecast shows a sustained bullish tilt, with sentiment remaining BULLISH across the horizon and averages moving higher through the 2030s and beyond.
In 2030, the forecast lists a min of $1,699.01, an avg of $2,184.91, and a max of $2,995.88, with a ROI of 77.6 and bullish sentiment. By 2040, the avg is projected at $6,030.94 with a min of $4,247.16 and max of $9,281.08, delivering a ROI of 390.4 and continued bullish sentiment. By 2050, the avg reaches $11,671.14 with a min of $7,639.29 and max of $19,286.19, yielding a ROI of 848.9 and a bullish outlook.
These figures are estimates and subject to market conditions; they are not guarantees of future results. The long-run trajectory signals meaningful upside potential if the forecast assumptions hold.
Tap a question to reveal the answer.
The 2030 forecast shows a min of $1,699.01, an avg of $2,184.91, and a max of $2,995.88, with a ROI of 77.6 and sentiment BULLISH.
Forecasts from 2027 onward show BULLISH sentiment with rising averages and a ROI up to 848.9 by 2050; the 2026 avg equals $1,229.93, with a neutral stance for that year.
The max forecast for 2030 is $2,995.88, which is just under $3,000.
The 30-day range is $1,081.43 to $1,398.82.
Current price is $1,229.93 and market cap is $1.1T.
Eli Lilly and Company Community Discussion
0Share your Eli Lilly and Company price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.